Nature Communications (Jul 2018)
Act1 is a negative regulator in T and B cells via direct inhibition of STAT3
- Cun-Jin Zhang,
- Chenhui Wang,
- Meiling Jiang,
- Chunfang Gu,
- Jianxin Xiao,
- Xing Chen,
- Bradley N. Martin,
- Fangqiang Tang,
- Erin Yamamoto,
- Yibo Xian,
- Han Wang,
- Fengling Li,
- R. Balfour Sartor,
- Howard Smith,
- M. Elaine Husni,
- Fu-Dong Shi,
- Ji Gao,
- Julie Carman,
- Ashok Dongre,
- Susan C. McKarns,
- Ken Coppieters,
- Trine N. Jørgensen,
- Warren J. Leonard,
- Xiaoxia Li
Affiliations
- Cun-Jin Zhang
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Chenhui Wang
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Meiling Jiang
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Chunfang Gu
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Jianxin Xiao
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Xing Chen
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Bradley N. Martin
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Fangqiang Tang
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Erin Yamamoto
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Yibo Xian
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Han Wang
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Fengling Li
- National Gnotobiotic Rodent Resource Center, Department of Medicine and Center for Gastrointestinal Biology and Disease, University of North Carolina
- R. Balfour Sartor
- National Gnotobiotic Rodent Resource Center, Department of Medicine and Center for Gastrointestinal Biology and Disease, University of North Carolina
- Howard Smith
- Department of Rheumatologic and Immunologic Disease, Cleveland Clinic
- M. Elaine Husni
- Department of Rheumatologic and Immunologic Disease, Cleveland Clinic
- Fu-Dong Shi
- Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital
- Ji Gao
- Discovery Biology, Bristol-Myers Squibb
- Julie Carman
- Discovery Biology, Bristol-Myers Squibb
- Ashok Dongre
- Discovery Biology, Bristol-Myers Squibb
- Susan C. McKarns
- Department of Surgery, University of Missouri School of Medicine
- Ken Coppieters
- Type 1 Diabetes Center, Novo Nordisk A/S
- Trine N. Jørgensen
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- Warren J. Leonard
- Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health
- Xiaoxia Li
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
- DOI
- https://doi.org/10.1038/s41467-018-04974-3
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 14
Abstract
Adaptor for IL-17 receptors (Act1) is known to be crucial for IL-17-mediated immune responses. Here the authors show that Act1 also functions as a negative regulator of T and B cells by direct inhibition of STAT3.
